This activity is intended for primary care physicians, neurologists, nurses, pharmacists, physician assistants, and other members of the healthcare team who treat and manage adults on antibiotic therapy.
The goal of this activity is that learners will be better able to assess the possible effect of antibiotic use on cognitive function among adults.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0 contact hours are in the area of pharmacology.
Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-22-118-H01-P).
Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 5/13/2023. PAs should only claim credit commensurate with the extent of their participation.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of
continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the
time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the
valid credit period that
is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in
your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as
the certificates from the
CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 5/13/2022
Valid for credit through: 5/13/2023, 11:59 PM EST
processing....
Healthcare professionals have experience in describing the potential negative consequences of inappropriate antibiotic use, including adverse events and a higher risk for incident resistant bacteria. However, many clinicians do not consider the potential long-term health effects of antibiotic prescriptions, which might be related to changes in the microbiome. A previous study by Petrelli and colleagues provides a systematic review of the relationship between antibiotic use and incident cancer. Their results were published in the August 2019 issue of Cancers.[1]
The researchers found 25 observational studies of the risk for cancer after antibiotic prescriptions, which included a total of nearly 8 million people. Overall, the odds ratio (OR) for incident cancer in comparing individuals who received antibiotics vs those who did not was 1.18 (95% confidence interval [CI], 1.12-1.24). The researchers found that antibiotic use was associated with higher risks for lung cancer, lymphomas, pancreatic cancer, renal cell carcinoma, and multiple myeloma. Beta lactams, cephalosporins, macrolides, and quinolones were all associated with a higher risk for cancer.
Previous research has found a link between antibiotic use and the risk for neuropsychiatric illness, but data on antibiotic use and cognitive decline are lacking. The current study addresses this issue.
A new study, published online March 23 in PLOS ONE, suggests that prolonged use of antibiotics in midlife is related to cognitive decline several years down the road.[2]
For the study, scientists paired self-reported antibiotic use of more than 14,000 middle-aged nurses with outcomes on neuropsychological tests conducted 7 years later. The results revealed that those nurses who received antibiotics for at least 2 months during a period of 4 years had lower scores on tasks involving memory, learning, attention, and psychomotor speed. Overall, the negative effects of antibiotics on cognition were comparable to those caused by 3 to 4 years of aging.
Although Andrew Chan, MD, MPH, a gastroenterologist at Harvard Medical School who co-led the study, does not preclude the possibility that the antibiotics might have acted directly on the brain, he told Medscape Medical News that his leading hypothesis is that the drugs had disruptive effects on the gut microbiota. Indeed, research on mice shows that antibiotics such as ampicillin, although undetectable in the brain, are linked to gut dysbiosis and cognitive impairment.[3]
A previous study on humans showed that those afflicted with Alzheimer's dementia had altered gut microbiome compared with healthy volunteers.[4] They had, for instance, more bacteria from the genus Bacteroides and less of those from the genus Bifidobacterium. Other research has revealed changes in diversity and decreased richness of gut microbes in several other conditions, from Crohn's disease and autism spectrum disorder to multiple sclerosis and Parkinson's disease.
"Numerous animal studies, and some human studies as well, have shown that gut dysbiosis is linked to cognitive impairment as well as brain alterations," Viktoriya Nikolova, MRes, MSc, a PhD student and researcher at King's College London, told Medscape Medical News when asked for independent comment. Antibiotics can cause changes in the microbiome that may last months or even years.[5,6]
There are many ways in which the trillions of microbes that reside in the human gut may affect the mind. They can hack into the vagus nerve, release neurotransmitters into the blood that crosses into the brain and interact with immune cells.
According to Dr Chan, "antibiotics and the disruption of the gut microbiome may trigger a chronic state of inflammation that predisposes people to develop cognitive decline." Such inflammation could be caused, for instance, by bacterial endotoxins, which are potentially toxic compounds released by gram-negative bacteria, such as Bacteroides, which are found in abundance in the guts of patients with Alzheimer's disease.
Experiments show that injecting mice with endotoxins can lead to greater formation of amyloid plaques, which are insoluble clumps of misfolded proteins that form between nerve cells in the brain, potentially blocking cell-to-cell signaling.[7] Rodent research suggests that antibiotics can indeed affect the formation of amyloid plaques.[8]
Although the new study in PLOS ONE adds to our knowledge of the potential negative effects of antibiotics on brain health, Dr Chan believes that it is too early to make any recommendations about whether people should avoid antibiotics specifically out of concern regarding dementia.
He does believe, however, that the study "does provide some additional rationale for being careful about how one uses antibiotics." Considering that the Centers for Disease Control and Prevention estimates that at least 30% of outpatient antibiotic prescriptions in the US are unnecessary, that is certainly a cause for concern.[9]
The study was independently supported. Dr Chan and Dr Nikolova have disclosed no relevant financial relationships.
PLoS One. Published online March 23, 2022.